Navigation Links
How is H pylori adhesion to gastric cells associated with MUC1 mucin VNTR size?
Date:3/18/2008

The Gram negative bacterium H pylori is involved in the pathogenesis of several gastrointestinal diseases, ultimately leading to gastric carcinoma. Adhesion of the bacteria to the gastric mucosa is an essential step for colonization and infection.

It is therefore important to know factors that influence the binding of the bacteria to gastric cells. MUC1, a mucin with a highly variable repetitive region (VNTR), has been recently identified as an H pylori binding target. In this work we tested the hypothesis that MUC1 VNTR polymorphism affects H pylori adhesion to gastric cells and thus plays an important role in the colonization of gastric mucosa.

Enzyme linked immunosorbent assay (ELISA)-based adhesion assays were performed to measure the adhesion of different H pylori strains (HP26695 and HPTx30a) to gastric carcinoma cell lines (GP202 and MKN45) and GP202 clones expressing recombinant MUC1 with different VNTR lengths. The research article to be published on March 7, 2008 in the World Journal of Gastroenterology.

The results showed that MUC1 VNTR polymorphism influences the binding of H pylori to gastric cells, with the higher adhesion levels observed in clones with larger VNTR regions. Furthermore, higher adhesion was observed in co-cultures with the pathogenic strain (HP26695) when compared to the non-pathogenic strain (HPTx30a) and GP202 cell line when compared to the MKN45 cell line. This work contributes to the understanding of the interplay between host and bacterial factors in H pylori infection pathogenesis.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. A low prevalence of H pylori in HIV-positive patients
2. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
3. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
4. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
5. MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
6. EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures
7. Gastric cancer survivors should be aware of osteoporosis
8. Gastric Lap-Band Surgery Can Send Diabetes Into Remission
9. Optimal band imaging with endoscopy facilitates the diagnosis of depressed-type early gastric cancer
10. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
11. Brain cells work differently than previously thought
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... Orbita’s ... on Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and IoT: ... Connected Home Event hosted by Parks Associates, a market research and consulting firm ...
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., ... pen. "My wife’s hand was damaged in a firework accident, so she couldn’t grip ... with manual problems." , He then designed and created a prototype for the HELPEN ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: